Skip to content
MedCompare

Leuprolide

Cancer & Oncology
Save $9,288/mo
10× cheaper

VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

United States
$10,330
per month
India
$1,042
per month
You save
$9,288
90% cheaper in India
41.1K US scripts/yr$381.8M potential annual savings$424.7M US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC59H84N16O12

SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6

Compare the price
US price$10,330per month
India price$1,042per month
You save$9,28890% less

Based on 30 units per month. US $344.33 vs India $34.75 per unit.

Total over 1 periodSave $9,288$10,330 → $1,042
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$55,725
Estimated travel cost
− $2,300
Net savings after travel
$53,425

Even after travel, you could come out ahead by about $53,425.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Leuprolide is filled about 41.1K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$424.7M
If sourced from India
$42.9M
Potential annual savings
$381.8M
−90%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.